A review of vaccine research and development: human acute respiratory infections.
A review of vaccine research and development: human acute respiratory infections.
复制标题
DOI：
10.1016/j.vaccine.2005.07.046
复制
发表时间：
2005-12-30
期刊：
影响因子：
5.5
通讯作者：
Kieny MP
中科院分区：
文献类型：
--
作者：
Girard MP;Cherian T;Pervikov Y;Kieny MP
在世界范围内，急性呼吸道感染（阿里斯）是急性疾病的主要原因，每年造成近400万人死亡，其中大多数是发展中国家的幼儿和婴儿。导致阿里斯的主要传染源包括流感病毒、呼吸道合胞病毒（RSV）、副流感病毒3型（PIV-3）、肺炎链球菌和流感嗜血杆菌。虽然流感疫苗是有效的，但H.流感病毒B型（HiB）和S.肺炎病毒感染已经可用了几年，但目前没有疫苗可用于对抗由RSV、PIV-3、偏肺病毒或三种新型冠状病毒中的任何一种引起的疾病。此外，过去几年中多次爆发禽流感所构成的威胁迫切要求开发具有更广泛功效的新型流感疫苗，其可以提供针对禽流感病毒大流行的免疫力。本文综述了阿里斯疫苗研发的最新进展，并试图解决这些基本的公共卫生问题。
Worldwide, acute respiratory infections (ARIs) constitute the leading cause of acute illnesses, being responsible for nearly 4 million deaths every year, mostly in young children and infants in developing countries. The main infectious agents responsible for ARIs include influenza virus, respiratory syncytial virus (RSV), parainfluenza virus type 3 (PIV-3), Streptococcus pneumoniae and Haemophilus influenzae. While effective vaccines against influenza, H. influenzae type b (Hib) and S. pneumoniae infections have been available for several years, no vaccine is available at present against illnesses caused by RSV, PIV-3, metapneumovirus or any of the three novel coronaviruses. In addition, the threat constituted by the multiple outbreaks of avian influenza during the last few years is urgently calling for the development of new influenza vaccines with broader spectrum of efficacy, which could provide immunity against an avian influenza virus pandemic. This article reviews the state of the art in vaccine R&D against ARIs and attempts to address these basic public health questions.
登录
查看更多内容
影响因子：
168.9
作者：
Cutts, FT;Zaman, SMA;Adegbola, RA
通讯作者：
Adegbola, RA
影响因子：
7.7
作者：
de Andrade, ALSS;de Andrade, JG;Fabio, JLD
通讯作者：
Fabio, JLD
影响因子：
5.4
作者：
Chen, DX;Weis, KF;Payne, LG
通讯作者：
Payne, LG
影响因子：
2.8
作者：
Ellis, TM;Bousfield, RB;Peiris, JSM
通讯作者：
Peiris, JSM